Cart
sales@molnova.com
YLC2-155
CAS No. 1354742-60-1
YLC2-155( YLC 2-155 | YLC2155 )
Catalog No. M11447 CAS No. 1354742-60-1
YLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameYLC2-155
-
NoteResearch use only, not for human use.
-
Brief DescriptionYLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT.
-
DescriptionYLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT; binds at the RNase H (RNH)-active site in multiple conformations; demonstrates inhibition of fully infectious HIV-1 (strain NL4-3) with EC50 of 6.7 uM in cell-based assays.
-
In Vitro——
-
In Vivo——
-
SynonymsYLC 2-155 | YLC2155
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1354742-60-1
-
Formula Weight243.22
-
Molecular FormulaC13H9NO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name7-(furan-2-yl)-2-hydroxyisoquinoline-1,3(2H,4H)-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kirby KA, et al. Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01351-17.
2. Kirby KA, et al. Antimicrob Agents Chemother. 2012 Apr;56(4):2048-61.
molnova catalog
related products
-
NBD-556
A potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction.
-
ALW-II-41-27
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
-
Doravirine
Doravirine (MK-1439, MK1439) is a novel, highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI) with IC50 of 12, 9.7, and 9.7 nM against WT, K103N, and Y181C reverse transcriptase (RT) mutants, respectively.
